Sanger, Illumina & Oxford Nanopore all read DNA.
But they go about it in completely different ways…🧵
8/ Throughput is 1 fragment per reaction, or 96/384 in parallel at most.
I still love it for
🧬plasmids (small circular DNA used as cloning vectors),
🧬confirming CRISPR edits,
🧬genotyping loci, &
🧬validating variants found by other methods.
Gold standard 🌟
15
9/ Its blind spot is mixed templates.
If two sequences are in the SAME tube, the peaks overlap & the chromatogram turns into soup.
That's a real headache with mixed-strain infections.
More (⏳5min read): adwoabiotech.blogspot.com/20…
6
Other delivery methods for gene editing:
Microinjection: a tiny NEEDLE delivers material directly into individual cells, often embryos.
1
58
19/ Bluebird bio's Zynteglo is another fascinating e.g.
It uses a lentiviral vector to introduce a functional β-globin gene into blood stem cells for β-thalassaemia.
US launch price: $2.8 million.
How does it compare with Casgevy as a β-thalassaemia treatment?
39
18/Then there's Zolgensma from Novartis.
It uses an AAV9 vector to deliver a functional SMN1 gene for spinal muscular atrophy.
Spinal muscular atrophy (SMA) is primarily a genetic disease that often presents in infancy or childhood, although it can also begin in adulthood.
47
17/ Viruses as delivery vehicles?
Spark Therapeutics developed Luxturna, using an engineered AAV to deliver a working RPE65 gene for certain inherited retinal diseases.
Its US launch price?
$850,000 for both eyes.
Mind you, this *isn't* CRISPR editing.
1
43
17.1/ RPE65, stands for Retinal Pigment Epithelium-specific 65 kDa protein.
It is a gene essential for normal vision, particularly in low-light conditions.
1
22
16/ LNPs aren't just for vaccines.
Onpattro (patisiran) uses lipid nanoparticles to deliver small interfering RNA (siRNA) to liver cells.
The siRNA reduces production of transthyretin, (the protein involved in hereditary amyloidosis).
No DNA editing here (gene silencing).
1
45
15/ What if Lipid Nanoparticles (LNPs) could deliver CRISPR?
Intellia Therapeutics, collaborating with Regeneron, is developing NTLA-2001 (nex-z).
It delivers Cas9 mRNA & guide RNA to the liver to edit the TTR* gene.
1
1
87













